MITP.F Stock Overview
Develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Mithra Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €6.75 |
| 52 Week High | €22.70 |
| 52 Week Low | €6.75 |
| Beta | 0.66 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| MITP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.2% |
| 1Y | n/a | 9.9% | 31.6% |
Return vs Industry: Insufficient data to determine how MITP.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MITP.F performed against the US Market.
Price Volatility
| MITP.F volatility | |
|---|---|
| MITP.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MITP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MITP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 300 | Leon Van Rompay | www.mithra.com |
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications.
Mithra Pharmaceuticals SA Fundamentals Summary
| MITP.F fundamental statistics | |
|---|---|
| Market cap | US$236.63m |
| Earnings (TTM) | -US$97.97m |
| Revenue (TTM) | US$23.00m |
10.3x
P/S Ratio-2.4x
P/E RatioIs MITP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MITP.F income statement (TTM) | |
|---|---|
| Revenue | €21.88m |
| Cost of Revenue | €14.56m |
| Gross Profit | €7.32m |
| Other Expenses | €100.55m |
| Earnings | -€93.23m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 33.46% |
| Net Profit Margin | -426.03% |
| Debt/Equity Ratio | 834.3% |
How did MITP.F perform over the long term?
See historical performance and comparison